FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel

TORONTO, August 16, 2018 /CNW/ – PRESS RELEASE – FSD Pharma Inc. has announced the launch of a clinical research collaborative program in Israel, via its strategic R&D partner, SciCann Therapeutics Inc.

This comprehensive clinical research program will be executed through SciCann’s strategic alliance and collaboration agreement with Mor Research Applications Ltd.–the technology transfer office and commercial arm of Clalit Healthcare Services, Israel’s largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel, employs over 9,000 physicians and serves the healthcare needs of over 50 percent of Israel’s population. 

As announced previously, FSD Pharma has secured the exclusive licensing rights for the manufacturing and distribution of SciCann’s line of proprietary, patent-pending, cannabinoid-based and indication-specific products in Canada.

Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of these products, in order to bring to market advanced and innovative cannabinoid-based products that are backed up by solid clinical data achieved through the highest standards of rigorous and objective clinical research typical for the development process of pharmaceutical products.  

Zeeshan Saeed, EVP and director of FSD Pharma, stated, “The launch of this clinical study collaboration program in Israel further demonstrates our focus and commitment to bringing disruptive science-based cannabinoid therapies to Canadian patients, and provide them with innovative cannabis products that have been tested and verified in rigorous clinical studies for the highest level of safety and efficacy.”

Dr. Zohar Koren, co-founder and CEO of SciCann, stated, “We are thrilled and excited to launch this strategic alliance and clinical research collaboration program with Mor Research Applications. Mor has gained substantial experience and proven track record in recent years in the efficient design and execution of large scale clinical studies with cannabinoid-based products for various hard-to-treat diseases such as GVHD (Graft Vs. Host Disease), ulcerative colitis, Crohn’s disease and more. Mor is the perfect strategic partner to enable the execution of a series of proof-of-concept rigorous clinical studies with our line of proprietary indication-specific cannabinoid-based products. We are looking forward eagerly to generating a large pool of much needed clinical data and hard evidence for the potential of cannabinoid-based therapies to treat a wide range of debilitating and hard to treat diseases, results that are much awaited by the global medical and clinical community of researchers in this unique field.”

Warrants Issued

In connection with certain consultant agreements entered into by FSD Pharma, it has issued 2.25 million warrants for class B subordinate voting shares at an exercise price of $0.13. The warrants expire one year from the date of issuance and include all required statutory hold periods.